Register for our free email digests:
Latest From Biogen Inc.
Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.
Local firm Yuhan is taking over from Merck as marketing partner in South Korea for Samsung Bioepis’ biosimilars amid speculation that weak sales of infliximab and etanercept may have triggered the realignment. Samsung Bioepis and Merck's broader partnership, however, remains intact.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.
- Gene Therapy, Cell Therapy
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Biogen Idec Inc.
- Biogen Inc.
- Idec Pharmaceutical Corp.
- North America
- Company Type
- 1st Tier Biotech
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
Michel Vounatsos, CEO
Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
Michael Ehlers, MD, PhD, EVP, R&D
Jean-Paul Kress, EVP, Pres., Intl. & Head, Global Therapeutic Ops.
Sanjay Jariwala, MD, SVP, Worldwide Medical
- Contact Info
Phone: (617) 679-2000
225 Binney St.
Cambridge, MA 02142
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.